Current treatment status-Undergoing active treatment-Partial response Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Partial response Posts on Medivizor

Evaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia

Posted by on Sep 13, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...

Read More

Evaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma

Posted by on Aug 17, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....

Read More

Looking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination

Posted by on Jul 21, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...

Read More

Using alpha-interferon to treat residual chronic myeloid leukemia after transplantation

Posted by on Jul 14, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of interferon-alpha (IntronA) treatment in patients with chronic myeloid leukemia (CML) with residual disease after transplantation. Researchers found that this treatment may be useful in patients with signs of disease after transplant. Some background Chronic myeloid leukemia is a cancer...

Read More

Evaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma

Posted by on Jun 16, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...

Read More

Evaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma

Posted by on Jun 5, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...

Read More

Evaluating brentuximab vedotin plus high-dose bendamustine for relapsed or unresponsive Hodgkin lymphoma

Posted by on May 31, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...

Read More

Evaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma

Posted by on May 11, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated  isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...

Read More

Evaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma

Posted by on Apr 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...

Read More

Evaluating long-term outcomes after radiation and stem cell transplantation for recurrent or unresponsive Hodgkin lymphoma

Posted by on Apr 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...

Read More

Evaluating PD-1 inhibitors for patients with Hodgkin lymphoma in a real-world setting

Posted by on Mar 26, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of PD-1 inhibitors for patients with classical Hodgkin lymphoma (cHL) outside of clinical trials. This study concluded that PD-1 inhibitors are safe and effective for these patients. Some background Standard first-line chemotherapy is highly effective in treating 70 – 80% of...

Read More